Additionally, the controlled modulation of the expression pattern of p53 isoforms, by antisense oligonucleotides at the RNA level [53,57], and by small molecules at the protein level [68], which could be an alternative approach in anti-cancer therapy applied in RCC in the future. The gene discussed is TP53; the disease is renal cell carcinoma.